Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction

Vascular Health and Risk Management

Volumn 4, Issue 6, 2008, Pages 1387-1400

  Frishman, William H ^a   Henderson, Linda S ^b   Lukas, Mary Ann ^b  

^a WESTCHESTER MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Beta blockers; Cardiovascular disease; Heart failure; Myocardial infarction; Vasodilatory

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ARRESTIN; CARVEDILOL; FREE RADICAL; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ASTHENIA; BETA ADRENERGIC RECEPTOR BLOCKING; BIOEQUIVALENCE; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED RELEASE FORMULATION; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; EXERCISE; FATIGUE; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART RATE; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOTENSION; IMMEDIATE RELEASE FORMULATION; INSULIN SENSITIVITY; INTRINSIC SYMPATHOMIMETIC ACTIVITY; LIPID PEROXIDATION; LOW DRUG DOSE; MICROALBUMINURIA; MONOTHERAPY; MORTALITY; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHARMACODYNAMICS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION; WEIGHT GAIN;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CARBAZOLES; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; HEART DISEASES; HEART FAILURE; HEMODYNAMICS; HUMANS; HYPERTENSION; MEDICATION ADHERENCE; PATIENT SATISFACTION; PROPANOLAMINES; QUALITY OF LIFE; TREATMENT OUTCOME; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 60249084170     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Al-Hesayen A, Azevedo ER, Floras JS, et al. 2005. Selective versus non-selective beta-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization. Eur J Heart Fail, 7:618-23.
2. American Heart Association. 2007. Heart Disease and Stroke Statistics - 2007 Update. Dallas, Texas: American Heart Association.
3. August P. 2003. Initial treatment of hypertension. N Engl J Med, 348:610-7.
4. Australia/New Zealand Heart Failure Research Collaborative Group. 1997. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet, 349:375-80.
5. Baird MG, Bentley-Taylor MM, Carruthers SG, et al. 1984. A study of efficacy, tolerance and compliance of once-daily versus twice-daily metoprolol (Betaloc) in hypertension. Betaloc Compliance Canadian Cooperative Study Group. Clin Invest Med, 7:95-102.
6. Bakris GL, Fonseca V, Katholi RE, et al. 2004. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA, 292:2227-36.
7. Bakris GL, Hart P, Ritz E. 2006a. Beta blockers in the management of chronic kidney disease. Kidney Int, 70:1905-13.
8. Bakris GL, Tarka EA, Waterhouse B, et al. 2006b. Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile. Am J Cardiol, 98:46L-52L.
9. Bangalore S, Kamalakkannan G, Parkar S, et al. 2007a. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med, 120:713-9.
10. Bangalore S, Messerli FH, Kostis JB, et al. 2007b. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol, 50:563-72.
11. Basat O, Ucak S, Seber S, et al. 2006. After myocardial infarction carvedilol improves insulin resistance compared to metoprolol. Clin Res Cardiol, 95:99-104.
12. Carter NJ, Keating GM. 2008. Controlled-release carvedilol. Am J Cardiovasc Drugs, 8:271-82.
13. Chobanian AV, Bakris GL, Black HR, et al. 2003. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42:1206-52.
14. Claxton AJ, Cramer J, Pierce C. 2001. A systematic review of the associations between dose regimens and medication compliance. Clin Ther, 23:1296-310.
15. Cleland JG, Charlesworth A, Lubsen J, et al. 2006. A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET). J Am Coll Cardiol, 47:1603-11.
16. Colagiuri S, Cull CA, Holman RR. 2002. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? UK prospective diabetes study 61. Diabetes Care, 25:1410-7.
17. Cushman WC, Ford CE, Cutler JA, et al. 2002. Success and predictors of blood pressure control in diverse North American settings: the anti-hypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich), 4:393-404.
18. Dandona P, Ghanim H, Brooks DP. 2007. Antioxidant activity of carvedilol in cardiovascular disease. J Hypertens, 25:731-41.
19. Dargie HJ. 2001. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet, 357:1385-90.
20. Doughty RN, Whalley GA, Walsh HA, et al. 2004. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation, 109:201-6.
21. Egan BM, Basile J, Chilton RJ, et al. 2005. Cardioprotection: the role of beta-blocker therapy. J Clin Hypertens (Greenwich), 7:409-16.
22. Fonarow GC. 2004. Managing the patient with diabetes mellitus and heart failure: issues and considerations. Am J Med, 116(Suppl 5A):76S-88S.
23. Fonarow GC. 2006. Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol. Expert Opin Pharmacother, 7:2533-46.
24. Fonarow GC, Lukas MA, Robertson M, et al. 2007. Effects of carvedilol early after myocardial infarction: analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN). Am Heart J, 154:637-44.
25. Frishman WH. 1998. Carvedilol. N Engl J Med, 339:1759-65.
26. Frishman WH. 2003. Alpha- and beta-adrenergic blocking drugs. In: Frishman WH, Sonnenblick EH, Sica DA (eds). Cardiovascular pharmacotherapeutics. 2nd ed. New York: McGraw Hill. p 67-97.
27. Frishman WH. 2007a. A historical perspective on the development of beta-adrenergic blockers. J Clin Hypertens, 9(4 Suppl 3):19-27.
28. Frishman WH. 2007b. Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens. Cardiol Rev, 15:257-63.
29. Giugliano D, Acampora R, Marfella R, et al. 1997. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med, 126:955-9.
30. Goldhammer E, Maor I, Shnitzer S, et al. 2007. The early anti-oxidant effect of carvedilol predicts the clinical course in congestive heart failure patients. J Cardiovasc Med (Hagerstown), 8:453-6.
31. Greenberg BH, Mehra M, Teerlink JR, et al. 2006. COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure. Am J Cardiol, 98:53L-9L.
32. Hauptman PJ, Pressler SJ, Sackner-Bernstein J, et al. 2006. Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol JR in patients with heart failure. Am J Cardiol, 98:60L-6L.
33. Henderson LS, Tenero DM, Baidoo CA, et al. 2006. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. Am J Cardiol, 98:17L-26L.
34. Henderson LS, Tenero DM, Campanile AM, et al. 2007. Ethanol does not alter the pharmacokinetic profile of the controlled-release formulation of carvedilol. J Clin Pharmacol, 47:1358-65.
35. Jacob S, Rett K, Wicklmayr M, et al. 1996. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens, 14:489-94.
36. Johnson ML, Pietz K, Battleman DS, et al. 2004. Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease. Am J Manag Care, 10:926-32.
37. Kozlovski VI, Lomnicka M, Chlopicki S. 2006. Nebivovol and carvedilol induce NO-dependent coronary vasodilatation that is unlikely to be mediated by extracellular ATP in the isolated guinea pig heart. Pharmacol Rep, 58(Suppl):103-10.
38. Kurum T, Tatli E, Yuksel M. 2007. Effects of carvedilol on plasma levels of pro-inflammatory cytokines in patients with ischemic and nonischemic dilated cardiomyopathy. Tex Heart Inst J, 34:52-9.
39. Lefkowitz RJ, Rajagopal K, Whalen EJ. 2006. New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors. Mol Cell, 24:643-52.
40. Leventhal MJ, Riegel B, Carlson B, et al. 2005. Negotiating compliance in heart failure: remaining issues and questions. Eur J Cardiovasc Nurs, 4:298-307.
41. Lindholm LH, Carlberg B, Samuelsson O. 2005. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet, 366:1545-53.
42. Maack C, Cremers B, Flesch M, et al. 2000. Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. Br J Pharmacol, 130:1131-9.
43. Maggi E, Marchesi E, Covini D, et al. 1996. Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J Cardiovasc Pharmacol, 27:532-8.
44. Manley S. 2003. Haemoglobin Alc - a marker for complications of type 2 diabetes: the experience from the UK Prospective Diabetes Study (UKPDS). Clin Chem Lab Med, 41:1182-90.
45. McGill JB, Bakris GL, Fonseca V, et al. 2007. beta-Blocker use and diabetes symptom score: results from the GEMINI study. Diabetes Obes Metab, 9:408-17.
46. McMurray J, Kober L, Robertson M, et al. 2005. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol, 45:525-30.
47. Messerli FH, Grossman E. 2004. beta-Blockers in hypertension: is carvedilol different? Am J Cardiol, 93:7B-12B.
48. Metra M, Giubbini R, Nodari S, et al. 2000. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation, 102:546-51.
49. Moreno AJ, Santos DJ, Palmeira CM. 1998. Ischemic heart disease: the role of mitochondria - carvedilol prevents lipid peroxidation of mitochondrial membranes. Rev Port Cardiol, 17(Suppl 2):II63-77.
50. Nakamura K, Kusano K, Nakamura Y, et al. 2002. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation, 105:2867-71.
51. Nichols AJ, Sulpizio AC, Ashton DJ, et al. 1989. The interaction of the enantiomers of carvedilol with alpha 1- and beta 1-adrenoceptors. Chirality, 1:265-70.
52. Othman AA, Tenero DM, Boyle DA, et al. 2007. Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate. Aaps J, 9:E208-18.
53. Otterstad JE, Ford I. 2002. The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials? Eur J Heart Fail, 4:501-6.
54. Packer M, Bristow MR, Cohn JN, et al. 1996. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med, 334:1349-55.
55. Packer M. 1998. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis, 41:39-52.
56. Packer M, Fowler MB, Roecker EB, et al. 2002. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation, 106:2194-9.
57. Packer M, Lukas MA, Tenero DM, et al. 2006. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. Am J Cardiol, 98:39L-45L.
58. Padi SS, Chopra K. 2002. Salvage of cyclosporine A-induced oxidative stress and renal dysfunction by carvedilol. Nephron, 92:685-92.
59. Patel PA, Tilley DG, Rockman HA. 2008. Beta-Arrestin-Mediated Signaling in the Heart. Circ J, 72:1725-9.
60. Pedersen ME, Cockcroft JR. 2007. The vasodilatory beta-blockers. Curr Hypertens Rep, 9:269-77.
61. Podbregar M, Voga G. 2002. Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure. J Card Fail, 8:369-78.
62. Poole-Wilson PA, Swedberg K, Cleland JG, et al. 2003. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet, 362:7-13.
63. Rao RB, Goldfrank LR. 1998. Fixed-dose combination therapy: panacea or poison? Intensive Care Med, 24:283-5.
64. Rasmussen JN, Gislason GH, Rasmussen S, et al. 2007. Use of statins and beta-blockers after acute myocardial infarction according to income and education. J Epidemiol Community Health, 61:1091-7.
65. Rosamond W, Flegal K, Furie K, et al. 2008. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 117:e25-146.
66. Stamler J, Wentworth D, Neaton JD. 1986. Prevalence and prognostic significance of hypercholesterolemia in men with hypertension. Prospective data on the primary screenees of the Multiple Risk Factor Intervention Trial. Am J Med, 80:33-9.
67. Stanley WC, Recchia FA, Lopaschuk GD. 2005. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev, 85:1093-129.
68. Sundberg S, Tiihonen K, Gordin A. 1987. Vasodilatory effects of carvedilol and pindolol. J Cardiovasc Pharmacol, 10(Suppl 11):S76-80.
69. Tatli E, Kurum T. 2005. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy. Can J Cardiol, 21:344-8.
70. Tenero DM, Henderson LS, Baidoo CA, et al. 2006. Pharmacokinetic properties of a new controlled-release formulation of carvedilol. Am J Cardiol, 98:5L-16L.
71. Toda N. 2003. Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther, 100:215-34.
72. Torp-Pedersen C, Poole-Wilson PA, Swedberg K, et al. 2005. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure - COMET. Am Heart J, 149:370-6.
73. Torp-Pedersen C, Metra M, Charlesworth A, et al. 2007. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart, 93:968-73.
74. Udelson JE, Pressler SJ, Sackner-Bernstein J, et al. 2007. Compliance with Once Daily Controlled Release vs Twice Daily Immediate Release Carvedilol in Patients with Heart Failure: The CASPER Trial J Card Fail, 13:S135.
75. Vittorio TJ, Zolty R, Kasper ME, et al. 2008. Differential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failure. J Cardiovasc Pharmacol Ther, 13:51-7.
76. Wallhaus TR, Taylor M, DeGrado TR, et al. 2001. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation, 103:2441-6.
77. Weber MA, Bakris GL, Tarka EA, et al. 2006a. Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. J Clin Hypertens (Greenwich), 8:840-9.
78. Weber MA, Sica DA, Tarka EA, et al. 2006b. Controlled-release carvedilol in the treatment of essential hypertension. Am J Cardiol, 98:32L-8L.
79. Wisler JW, DeWire SM, Whalen EJ, et al. 2007. A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A, 104:16657-62.
80. World Health Organization. 2007. Cardiovascular diseases. Fact sheet no. 317 [online]. Accessed August 4, 2008. URL: http://www.who.int/ mediacentre/factsheets/fs317/en/index.html.
81. Wright JT Jr, Bakris GL, Bell DS, et al. 2007. Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial. J Clin Hypertens (Greenwich), 9:842-9.
82. Yang SP, Ho LJ, Cheng SM, et al. 2004. Carvedilol differentially regulates cytokine production from activated human peripheral blood mononuclear cells. Cardiovasc Drugs Ther, 18:183-8.